Director, Chief Executive Officer · Veraxa Biotech AG - Post de-SPAC · Ordinary Shares
Side
BUY
Value
$7,650
Shares
5,000
Price
$1.53
Executed
Aug 27, 2026
Disclosed
Aug 31, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Aug 27 executedAug 31, 2026 disclosed
VRXA · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering+5 / 15
1 other actor traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Antz Christoph Rudiger filed this Form 4 reporting a open-market purchase of VRXA on Aug 27, 2026. It became public on Aug 31, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, Chief Executive Officer
Antz Christoph Rudigercik:0002123284
Issuer
Veraxa Biotech AG - Post de-SPACcik:0002079109
Revision history · 0
No field has changed since this record was first ingested.
